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The Pathogenesis and Prevention of Diabetic Neuropathy and Nephropathy 
Douglas Greene 
The chronic complications of diabetes are thought to be caused by an interaction between hyperglycemia, or other 
metabolic consequences of insulin deficiency, and independent genetic or environmental factors that are poorly defined. 
Several potentially relevant biochemical sequelae to hyperglycemia have been identified in tissue susceptible to diabetic 
complications. Among these, a rise in tissue sorbitol secondary to concentration-dependent activation of polyol pathway 
activity by glucose, and an accompanying fall in tissue myo-inositol and Na-K-ATPase activity have recently been linked to a 
self-reinforcing cyclic metabolic defect that accounts for rapidly reversible slowing of conduction in peripheral nerve in 
diabetes. Impaired Na-K-ATPase activity also appears to be responsible for intracellular Na+ accumulation and resultant 
localized axonal paranodal swelling that characterizes diabetic neuropathy in both humans and laboratory animals. These 
swellings are thought to be responsible for the subsequent disruption of the nodal apparatus faxo-glial disjunction) and 
some component of the loss of large and small myelinated fibers. Recent studies have suggested that microvascular 
insufficiency may also contribute to diabetic neuropathy, especially in non-insulin-dependent diabetes. Aldose reductase 
activity is concentrated in endoneurial vessels, and similar biochemical mechanisms (ie, sorbiiol accumulation, myo-inositol 
deficiency, and impaired Na-K-ATPase activity) are thought to be operative in the endoneurial microvessals in diabetes. 
Administration of an atdose reductase inhibitor to patients with diabetic neuropathy is associated with repair of damaged 
nerve fibers and the appearance of newly generated fibers, presumably secondary to metabolic correction within the nerve 
fibers themselves or their supporting microvasculature. Components of this same biochemical pathway have now been 
identified in the renal glomerulus and the retina, which may implicate this metabolic sequence in the pathogenesis of 
multiple diabetic complications. 
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0 NE OF THE MOST persistent, controversial, and important questions concerning diabetes is whether the 
so-called glucose hypothesis of diabetic complications is 
correct. Essentially, the hypothesis is that hyperglycemia 
and/or insulin deficiency leads to secondary biochemical 
abnormalities in target tissues, which are followed by altera- 
tions in the functions of these tissues, the appearance of 
structural lesions, and, ultimately, clinical complications. In 
addition, at each point in this sequence of events, indepen- 
dent genetic or environmental variables seem to alter the 
expression of these complications. The results of one study 
indicate that male diabetics are more likely to develop 
diabetic neuropathy than their female counterparts, despite 
similar duration of disease and degree of hyperglycemia, and 
that taller individuals are more likely to develop diabetic 
neuropathy than shorter ones, even after correction of gly- 
cosylated hemoglobin and duration of diabetes.’ Other stud- 
ies indicate that the development of diabetic neuropathy 
seems to be accelerated by alcohol consumption and nutri- 
tional deficiencies.**-\ 
If the modified glucose hypothesis of diabetic complica- 
tions is correct, there should first be a logical sequence of 
events that starts with glucose and ends with a clinical 
complication. Secondly, this hypothesis should in some way 
address the well-known clinical variability of diabetic com- 
plications. Diabetic neuropathy embraces a tremendously 
varied spectrum of disease. A patient with an acute onset of 
ptosis and diplopia who develops an isolated third nerve palsy 
presents an example of diabetic cranial neuropathy, a condi- 
tion that has a good chance of resolving within a year or SO.~ 
In contrast to this, the more common chronic indolent distal 
symmetric polyneuropathy arising over 10 to 15 years tends 
to be progressive, despite temporary periods of remission.5 
Symptoms such as pain or paresthesias may resolve, but 
sensory deficits generally worsen from paresthesia to anes- 
thesia. 
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AUTONOMIC NEUROPATHY 
Autonomic neuropathy, which can involve virtually any of 
the visceral organs, tends to be progressive. One patient may 
present with severe gastroparesis with little clinical evidence 
of cardiovascular autonomic neuropathy, and another may 
present with orthostatic hypotension without obvious delayed 
gastric emptying. 
Widespread subclinical autonomic dysfunction is present 
in almost all patients with symptomatic autonomic neuropa- 
thy. Again, the disease may express itself differently in each 
person. The chronic progressive forms of diabetic neuropa- 
thy, distal symmetric polyneuropathy and autonomic neu- 
ropathy, exhibit widespread loss of large and small myeli- 
nated and unmyelinated fibers, as does autonomic neuropa- 
thy. Indeed, it is not uncommon for patients to lose two thirds 
or more of their myelinated nerve fibers. This loss is accom- 
panied by proliferation of endoneurial connective tissue and 
a series of vascular abnormalities, including thickening of the 
vascular basement membrane, capillary closure, and throm- 
botic occlusion within the peripheral nervous system.6 
Is this chronic destructive process related to blood glucose 
abnormalities? A study by Troni et al demonstrated that 
reducing hyperglycemia acutely improves nerve conduction 
velocity (Fig l).r Other studies have had similar results, 
suggesting that glucose or a glucose metabolite may acutely 
impair nerve function in diabetics.’ But what is the biochemi- 
cal mechanism responsible for changes in nerve function? 
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HCV: 1 0.6 m/s 
Quantitatively, the most impressive abnormality in nerve 
metabolism in diabetes is a diversion of glucose metabolism 
from oxidative to reductive pathways. Under normal circum- 
stances, glucose is primarily oxidized to carbon dioxide and 
water for efficient derivation of energy in the form of 
adenosine triphosphate (ATP) (Fig 2, left panel). When 
hyperglycemia is present, excess glucose enters the nerve 
because its transport is neither rate-limiting for metabolism 
nor insulin dependent. Glycolytic pathways become satu- 
rated and there is a marked increase in the reduction of 
sorbitol by the enzyme aldose reductase once glucose levels 
are elevated within peripheral nerves. The sorbitol is then 
metabolized to fructose by sorbitol dehydrogenase. 
THE SORBITOL PATHWAYS 
Is there a link between abnormal glucose metabolism 
through the sorbitol pathways and reversible abnormalities 
in nodal (nodes of Ranvier) function? It has been established 
that the enzyme aldose reductase is localized in the nodes of 
Ranvier,’ but to understand the effects of sorbitol pathway 
on nerve conduction, it is first necessary to understand 
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Fig 2. Schematic depiction of glucose metabolism in normal 
end diabetic nerve. 
Fig 1. Changes in mm conduction velocity over the 
Ii-reflex pethwey (n-WC) and blood gluceee during attifi- 
ciel endocrine pencrr8 treetment in indMduel petients. 
6, bareline; D, dotormination; BG. blood glucose. 
Reprinted with psrmiesion.’ 
nerve. When the sorbitol pathway was first intensively 
studied in diabetic peripheral nerve, independent studies 
were being conducted on the metabolism of myo-inositol in 
peripheral nerve. In studies of diabetic rats, myo-inositol 
levels were decreased in peripheral nerve, but administration 
of insulin prevented this decrease and improved nerve con- 
duction velocity.” Furthermore, myo-inosito1 depletion but 
did not lower elevated nerve glucose and sorbitol levels, 
restored normal nerve conduction velocity. Understandable, 
the so-called sorbitol hypothesis and the myo-inositol hypoth- 
esis were originally considered to be two independent hypoth- 
eses that attempted to explain acute and reversible changes 
in nerve conduction in experimental diabetic neuropathy. 
However, increasingly compelling evidence suggested that 
the biochemical defects were tightly intertwined.” 
In virtually every tissue prone to diabetic complications, a 
rise in sorbitol level is accompanied by evidence of myo- 
inositol depletion within the tissue; however, the exact mech- 
anism for this seesaw interrelationship is still not clear. The 
observation that myo-inositol depletion occurs in diabetic 
complications preceded our recognition that myo-inositol 
metabolism plays a unique role in cellular regulation. Myo- 
inositol belongs to a class of compounds called phosphoinosi- 
tides, which are metabolically labile phospholipids consisting 
of myo-inositol in phosphodiesterase linkage to a glycerol 
moiety containing two fatty acids, which are usually arachi- 
donic and stearic acid. 
PHOSPHOlNOSlTlDE METABOLISM 
Phosphoinositide hydrolysis is initiated by a variety of 
specific receptor mediated stimuli, yielding two important 
metabolically active intracellular metabolites, diacylglycerol 
and inositol polyphosphates, which modulate an array of cell 
functions. Diacylglycerol, a lipid-soluble metabolite, is an 
activator of protein kinase C, which phosphorylates a large 
number of intracellular proteins, thus modulating their activ- 
ity. Inositol polyphosphates, the water-soluble derivatives of 
phosphoinositides, have marked effects on intracellular cal- 
cium metabolism. Therefore, myo-inositol through its incor- 
Fig 3. Schematic representation 
pump 
of a node of Ranvisr, illustrating the 
c71 
+ 
sodium pump (left) and voltage- 
dependent sodium channels fright) 
embedded in the axon membrane. 3Na’ 2K’ 
poration into phospholipids plays a very important role in 
transmembrane signaling and in the regulation of intracellu- 
lar metabolism. Thus, hyperglycemia stimulates polyol path- 
way activity, which leads to myo-inositol depletion, which in 
turn leads to derangements in phosphoinositide-mediated 
transmembrane signal transduction, which then leads to 
interference with cell function. 
Do alterations in phosphoinositide metabolism contribute 
to abnormal function of the nodes of Ranvier? A node of 
Ranvier contains three important functional elements: (1) 
the axonal membrane, (2) a sodium pump or Na-K-ATPase 
that generates an electrochemical sodium gradient across the 
membrane, and (3) a series of voltage-sensitive sodium 
channels that become permeable to sodium in the presence of 
a depolarizing voltage and discharge the gradient generated 
by the Na-K-ATPase (Fig 3). As has been demonstrated in a 
series of biophysic and neurochemical studies, Na-K- 
ATPase activity is reduced in diabetic nerve, but if an 
accumulation of sorbitol is prevented by means of an aldose 
reductase inhibitor, the impairment of Na-K-ATPase is 
prevented. In addition, if sorbitol is allowed to accumulate, 
but myo-inositol depletion is prevented by administration of 
myo-inositol, the abnormalities of NA-K-ATPase and nerve 
conduction are also prevented.” Thus the NA-K-ATPase 
impairment in diabetic nerve is the result of myo-inositol 
depletion induced by sorbitol-pathway activation. 
The rapidly reversible component of nerve-conduction 
slowing can be largely attributed to impairment of the 
Na-K-ATPase, which in turn is secondary to myo-inositol 
depletion, sorbitol accumulation, and, ultimately, hypergly- 
cemia (Fig 4).‘* 
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Although these processes may explain the rapidly revers- 
ible slowing of nerve conduction in diabetic animals or 
patients, do they relate to the pathogenesis of clinically overt 
diabetic neuropathy? Obviously, painful paresthesias or clin- 
ically detectable sensory deficits are not easily explained 
simply on the basis of sodium pumps that are turned off. 
More likely, symptomatic diabetic neuropathy reflects the 
loss or severe damage to the majority of peripheral nerve 
fibers in patients with long-standing diabetes.’ 
Does the biochemical sequence clarify the development of 
severe structural abnormalities in peripheral nerve? Because 
the sodium pump plays a major role in the maintenance of 
the intracellular ionic environment, it is understandable how 
impairment of Na-K-AtPase function would lead to the 
swelling of cells. Indeed, the swelling of nerve fibers in the 
nodal and paranodal regions is the earliest structural lesion 
that occurs in diabetic rats.” Persistent swelling is thought to 
lead to subsequent disruption of the structural elements of 
the nodes of Ranvier (Fig S).” Under normal conditions, the 
myelin sheath is tightly applied to the axon membrane in the 
paranodal region, thereby maintaining the sodium channels 
in high concentration there. Persistent swelling of the nodes 
of Ranvier is associated with loss of these axo-glial junctions, 
which leads to early paranodal demyelination and loss of 
sodium channels from the nodal region (Fig 5). This is a 
relatively poorly reversible structural lesion, since once these 
channels are lost, metabolic correction does not rapidly 
restore their normal distribution, and hence nodal function 
and structural integrity remain impaired.14 
Does this sequence of events occur in human patients with 
diabetic neuropathy? As part of a recent multicenter trial of 
2K‘ 
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Fig 4. A Schwann cell, or exon, or 
both, in which hyperglycemia leads to 
activation of the polyol pathway, 
depleting some component of cell ino- 
sitol. Turnover of myo-inositol 
through the inositol-phospholipid cy- 
cle is thereby diminished, reducing the 
release of the second messengers 
such as diacyiglycerol. This leads to 
decreased activation of protein kinase 
C, shown here es a “hydraulic switch” 
that somehow turns Na-K-ATPaae on 
end off. With Na-K-ATPase off, it fails 
to maintain a normal sodium gradient 
across the cell membrane, diminishing 
the current flux when voltage-depen- 
dent sodium channels are opened, 
leading to impaired nerve conduction. 
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Fig 5. A node of Ranvier with normal axo-glial junctional 
complexes (stippled bands on left) and with disrupted axo-glial 
junctions (axo-glial disjunction, broken lines on right) that follow 
nodal swelling in insulin-deficient biobreeding rats. Voltage- 
dependent sodium channels are shown migrating through the 
disrupted axo-glial junctional complexes and into the internodal 
region of the axolemma (arrows). Reprinted with permission.” 
an aldose reductase inhibitor, nerve biopsies from subjects 
with diabetic neuropathy were examined for paranodal 
swelling and axo-glial disjunction. Both were found, 
although the presence of axo-glial disjunction was restricted 
to patients with insulin-dependent diabetesI Those with 
non-insulin-dependent diabetes exhibited additional lesions, 
more suggestive of an ischemic component having contrib- 
uted to their neuropathy. 
Histochemical studies localizing aldose reductase in nerve 
suggest that it is concentrated not only in the nodal region of 
myelinated nerve fibers, but also in the endoneurial vascula- 
ture, particularly the microvascular endothelial cell and 
pericyte.’ Thus, the same initiating factors (hyperglycemia, 
sorbitol accumulation, and myo-inositol depletion) may act 
at more than one tissue site within peripheral nerve, and the 
relative importance of these tissue sites may differ between 
insulin-dependent and non-insulin-dependent diabetes, per- 
haps because of differences in coexistent macrovascular 
disease. 
ALDOSE REDUCTASE INHIBITORS 
If a common mechanism is involved in the pathogenesis of 
neuropathy in insulin-dependent and non-insulin-dependent 
diabetes, then interruption of that mechanism might yield 
important therapeutic results. Preliminary data suggest that 
patients with diabetic retinopathy who are treated with 
aldose reductase inhibitors for 12 months exhibit significant 
improvement in their abnormal biochemistry and peripheral 
nerve morphology.‘6v’7 Unexpectedly, nerve fiber repair was 
accompanied by a brisk, early nerve fiber regeneration. The 
immaturity of these fibers makes it unlikely that an immedi- 
ate clinical effect would be detectable; however, extrapola- 
tion of the changes with more prolonged treatment should 
lead to a marked increase in the number of nerve fibers and, 
perhaps, reversal of clinical neurologic defects.” Heretofore 
this outcome was considered highly unlikely in patients with 
advanced, clinically overt diabetic neuropathy. 
Although the ultimate clinical effects of this treatment are 
still under investigation, this is probably the first example of 
reversal of a clinically overt complication of diabetes using a 
treatment directed against a specific sequela to hypergly- 
cemia. 
Thus, in peripheral nerve, hyperglycemia through activa- 
tion of the polyol pathway leads to changes in myo-inositol 
and phosphoinositide metabolism that impairs Na-K- 
ATPase activity, leading to swelling, damage, and ultimately 
loss of nerve fibers. These same biochemical processes may 
also blunt the cells’ ability to respond to the neurotropic 
factors that normally stimulate nerve regeneration in the 
presence of ongoing nerve damage. Correcting this inositol- 
phosphoinositide abnormality would therefore enhance 
response to the neurotropic factors that usually stimulate 
nerve cell regeneration. These biochemical, biophysic, and 
neuroanatomic abnormalities provide a basis on which to 
build an understanding of the pathogenesis and variability of 
diabetic neuropathy and its slow response to treatment when 
in its fully developed form. 
A similar pattern can be discerned in diabetic nephropa- 
thy. ‘* Renal disease affects non-insulin-dependent diabetics 
less than those who are insulin dependent, with fewer than 
10% of the former experiencing renal deficiency after 20 
years of disease. Indeed, in both animals with experimental 
diabetes and in humans with insulin-dependent diabetes, the 
major early functional abnormality is a hyperfunction of the 
kidney, with increased renal blood flow and hyperfiltration. 
The early increase in glomerular filtration rate (GFR) in 
patients with diabetic nephropathy is blood glucose-depen- 
dent, and Goldfarb et al demonstrated that administration of 
an aldose reductase inhibitor or myo-inositol prevents 
increased GFR,19 which is thought to be a contributing factor 
to the subsequent development of clinical nephropathy. Simi- 
larly, aldose reductase is highly localized to the retinal 
pericyte, the cell that exhibits the earliest structural change 
in diabetic retinopathy,” and alterations in myo-inositol 
metabolism and Na-K-ATPase function have also been 
identified in diabetic retina.“.** 
SUMMARY 
Thus, three complications, neuropathy, nephropathy, and 
retinopathy, exhibit a logical sequence that starts with 
hyperglycemia and proceeds towards clinically overt compli- 
cations. In the case of diabetic neuropathy, it appears that 
specific interruption of the biochemical abnormalities is 
likely to lead not only to stabilization, but also to at least 
partial reversal of this clinically overt complication of diabe- 
tes. The possibility that therapies that interrupt this bio- 
chemical sequence may become important elements in the 
prevention and reversal of the three major diabetic complica- 
tions holds great promise for the future. 
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